Phase II NSCLC Trial To Use Median's Imaging Services
MEDIAN Technologies announced that it has signed a contract with a San Francisco-area based biotech company
MEDIAN Technologies, a medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced that it has signed a contract with a San Francisco-area based biotech company to provide imaging services to support a phase II clinical trial for advanced non-small cell lung cancer.
The study is anticipating imaging data from 90 clinical sites, based in 12 European countries, in the US, and in Canada. Anticipated total enrollment is 440 patients with a "first patient in" forecasted May 2014. Median will supply a set of services including clinical site qualification and training, as well as image and data collection, quality control, and storage.
Read the full release here.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
